Recent Finacing
Recent Raise
Synthekine engineers cytokine partial agonists and surrogate VHH agonists to dimerize receptors, develops orthogonal IL-2 systems and cytokine-enhanced CAR‑T therapies, and advances IL-2 and IL-12 programs toward clinical trials.
